The Management of Immunosuppression

Abstract

The optimal use of immunosuppressant drugs requires an understanding of their mechanism of action as well as a basic understanding of the biology of transplant rejection and tolerance. The ability to tailor a drug regimen that strikes a fine balance between allograft maintenance and patient well-being demands a sensitivity to the patient's needs and expectations as well. The object of this article is to cover the basic biological principles involved in selecting an immunosuppressant protocol while sharing our experiences with these various regimen.

Decellularized Extracellular Matrix: The Role of This Complex Biomaterial in Regeneration

“…9,10 Currently, immunosuppression involves the use of 3 types of drugs: a calcineurin inhibitor, an antiproliferative agent, and corticosteroids. 11,12 In addition, it is possible to use monoclonal or polyclonal antibody therapy, which aims to prevent cases of acute rejection of the transplanted organ through T lymphocyte depletion. 13,14 Despite these difficulties, the main factor that limits the practice of transplants is the scarcity of suitable organs, from either the lack of donors or the low quality of available organs (virus-positive donors and recipients; blood group incompatibility; structural condition of the organ).…”

“…The drug regimens are used to suppress the immunity of recipient patients before and after the transplant procedure in order to prevent tissue rejection. However, at the same time, the drugs should be dosed to allow the immune system to maintain sufficient functionality to fight, e.g., infections. , Currently, immunosuppression involves the use of 3 types of drugs: a calcineurin inhibitor, an antiproliferative agent, and corticosteroids. , In addition, it is possible to use monoclonal or polyclonal antibody therapy, which aims to prevent cases of acute rejection of the transplanted organ through T lymphocyte depletion. , …”

“… 9 , 10 Currently, immunosuppression involves the use of 3 types of drugs: a calcineurin inhibitor, an antiproliferative agent, and corticosteroids. 11 , 12 In addition, it is possible to use monoclonal or polyclonal antibody therapy, which aims to prevent cases of acute rejection of the transplanted organ through T lymphocyte depletion. 13 , 14 …”

Dystrophin expression in host muscle following transplantation of muscle precursor cells modified with the phiC31 integrase

“…Tacrolimus (FK506) is currently the best immunosuppressive drug to prevent the rejection of MPCs, 1,2 but it induces some adverse effects. 3 To avoid the use of this immunosuppressive drug, our lab is focusing on the development of an ex vivo gene therapy based on the transplantation of autologous MPCs, derived from satellite cells or eventually from other types of stem cells obtained from the patient himself. These cells are genetically modified in vitro to express the normal dystrophin protein.…”